Back

Adaptive versus conventional cardiac resynchronization therapy in asian heart failure patients with moderately wide QRS: primary results from the Mid-Q Response randomized trial

30 March 2025 (08:00 - 15:30)
Organised by: Logo
Congress Presentation Part of: Device therapy 2 Cardiac Resynchronisation Therapy (CRT) EHRA Premium Access EHRA 2025 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Seung-Jung Park

Samsung Medical Center, Seoul (Korea (Republic of))

5 More presentations in this session

Presentation thumbnail
Primary prevention ICD implantation in non-ischemic cardiomyopathy patients: a retrospective analysis applying the 2023 Dutch Society of Cardiology Guidelines
Mr L. Hopman (Amsterdam, NL)
Abstract Slides Video
Presentation thumbnail
Predictors of late gadolinium enhancement image quality in patients with cardiac devices
Miss F. Amrani (Amsterdam, NL)
Abstract Slides Video
Presentation thumbnail
Conduction system versus right ventricular pacing for bradycardia treatment; 1 year outcomes of a prospective, randomized trial in patients with advanced AV disease
Doctor K. Curila (Prague, CZ)
Abstract Slides Video
Presentation thumbnail
Accurate machine learning classification of atrial high rate events with automated implementation in remote monitoring
Doctor A. Thiyagarajah (Bordeaux, FR)
Abstract Slides Video
Presentation thumbnail
Use of entrainment and overpacing of atrial tachyarrhythmias through CIED in outpatient clinic setting in locating site and termination of AT. Our experience of feasibility and reliability.
Doctor G. Criscione (Leiden, NL)
Abstract Slides Video

Access the full session

Session thumbnail
Device therapy 2
Video

The Event

Event poster

EHRA 2025

30 March - 1 April 2025
You may be interested in
thumbnail
Congress Presentation
Prediction of CRT response using a novel CRT responder score in an Asian patient population
thumbnail
Congress Presentation
Conclusions
thumbnail
Congress Presentation
Discussion - MORE-CRT MPP

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources